MedTrace Logo

Study of Multiple-dose Kukoamine B Mesilate in Healthy Volunteers

NCT02690961 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2017-05-03

No results posted yet for this study

Summary

The purpose of this study is to assess safety, tolerance and pharmacokinetics of Multiple-dose Kukoamine B Mesilate in healthy volunteers

Conditions

  • Healthy

Interventions

DRUG

Kukoamine B Mesilate

Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.

DRUG

placebo multiple doses

Sponsors & Collaborators

  • Southwest Hospital, China

    collaborator OTHER

  • Tianjin Chasesun Pharmaceutical Co., LTD

    lead INDUSTRY

Principal Investigators

  • Shuai Chen · Tianjin Chasesun Pharmaceutical Co., LTD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2016-06-14
Completion
2016-06-14

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02690961 on ClinicalTrials.gov